UKRI CDT IN Biomedical AI w/ Julien Fauqueur

How BenevolentAI leverages ML and AI to develop life-changing medicines

Join Julien Fauqueur, Lead AI Scientist at BenevolentAI, for a  talk on how BenevolentAI combines AI with cutting edge science to de-risk drug discovery. Julien will give an introduction to BenevolentAI to the UKRI CDT Uni.Ed PhD students, and explore how we use machine learning and natural language processing to extract biomedical facts from literature, identify targets and, identify patient subgroups.

Register here →

Julien Fauqueur

Lead AI Scientist

As Lead AI scientist at BenevolentAI, Julien Fauqueur leads and develops novel NLP methods for Biomedical Information Extraction. He holds a PhD in Computer Science from INRIA (France). While a research associate at the University of Cambridge, then as as a researcher in industry, he delivered innovative products using computer vision and machine learning methods. His work was published in over 25 publications and led to 5 patents.

More Posts

You Might Also Like

BenevolentAI achieves third milestone in its AI-enabled drug discovery collaboration with AstraZeneca
AstraZeneca selects another novel target for idiopathic pulmonary fibrosis from the collaboration for its drug development portfolio.
May 17, 2022
FDA converts emergency approval of baricitinib — first identified as a COVID treatment by BenevolentAI — to a full approval
The FDA has converted its emergency approval of baricitinib to a full approval, underscoring the strength of BenevolentAI’s AI-derived hypothesis.
May 12, 2022
Notifications of persons discharging managerial responsabilities
May 5, 2022
PDMR Notification (Dr. Olivier Brandicourt)
May 5, 2022
PDMR Notification (Jean Raby)
May 5, 2022
Notifications of Major Holdings
Apr 29, 2022